 Prostate specific antigen irradiation prostatic carcinoma clinical significance serum prostate specific antigen primary irradiation adenocarcinoma prostate uncertain Between September December serial prostate specific antigen values patients definitive radiation therapy study group patients stage stage stage stage disease mean pre-treatment prostate specific antigen level patients first post-treatment prostate specific antigen level pre-treatment level patient recurrent prostatic cancer rectum patients symptomatic metastases prostate specific antigen level months detection recurrence absolute value trend prostate specific antigen patients high intermediate low risk distant metastases high intermediate low risk patients recurrent disease serial post-irradiation prostate specific antigen values useful early identification patients risk treatment failure